Mereo BioPharma (MREO) Non-Current Assets (2017 - 2026)

Mereo BioPharma (MREO) has reported Non-Current Assets for 10 consecutive years, with $1.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Assets rose 8.51% year-over-year to $1.3 million in Q2 2026; TTM through Jun 2026 was $4.0 million, a 36.57% decrease from a year earlier, with the FY2025 full-year figure at $897000.0, down 44.87% from the prior year.
• Non-Current Assets was $1.3 million for Q2 2026 at Mereo BioPharma, up from $580000.0 in the prior quarter.
• Over five years, Non-Current Assets peaked at $2.7 million in Q4 2023 and troughed at -$103.0 million in Q2 2022.
• A 5-year average of -$16.2 million and a median of $1.3 million in 2025 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets jumped 103.76% in 2023 and sank 59.24% in 2026, its largest moves.
• Over 5 years, Non-Current Assets stood at -$72.9 million in 2022, then jumped by 103.76% to $2.7 million in 2023, then sank by 40.6% to $1.6 million in 2024, then slumped by 44.87% to $897000.0 in 2025, then soared by 46.38% to $1.3 million in 2026.
• The last three Non-Current Assets figures came in at $1.3 million (Q2 2026), $580000.0 (Q1 2026), and $897000.0 (Q4 2025), per Business Quant data.